Latest News

Medlab Clinical (ASX:MDC) has entered into a collaborative agreement with Chronic Pain Australia regarding consumer and health practitioner medicinal cannabis education throughout Australia.

"We know that the fastest way to get access to the latest drugs and treatments available in the world is through clinical trials. This is also the only way to develop the evidence needed to list treatments on the PBS and MBS – providing access for all," said Labor leader Bill Shorten.

Immuron (ASX:IMC) has announced the appointment of its CEO, Dr Gary Jacob, to the Board of Directors.

Melbourne-based mental health technology company Medibio (ASX:MEB) has announced a 'Sponsored Research Agreement' with the Department of Biomedical Sciences of Humanitas University in Milan.

"Novartis is delighted about today’s announcement and the difference this therapy will make to patients in Australia," said Lauren Carey, general manager Oncology and country president, Novartis Australia and New Zealand.

The company said the implant is designed for routine 1.5 and 3 Tesla magnetic resonance imaging scans without the need to remove the internal magnet.

MGC Pharmaceuticals (ASX:MXC) says it has received a UK Controlled Drug Import Licence permit for the importation of CannEpil.

Leading digital health company ResApp Health (ASX:RAP) has announced it has submitted an application to the US FDA for De Novo classification of its ResAppDx-US - a mobile software application for the diagnosis of paediatric respiratory disease using cough sounds.

Former AusBiotech CEO and current Medicines Australia chair Dr Anna Lavelle has been recognised for her leadership of the life sciences sector.

According to Grant Thornton's Sukvinder Heyer, Australia has a successful, clear and robust R&D support program, but must continually find ways to maintain a competitive edge in a global market.

Factor Therapeutics (ASX:FTT), a Brisbane-based company focused on developing and commercialising advanced wound care therapies, has announced the appointment of Dr David Brookes as a non-executive director.

Alterity Therapeutics, formerly known as Prana Biotechnology (ASX:PBT), has announced it is meeting with sophisticated investors in both Singapore and Hong Kong in the first leg of a global investor roadshow.